Intercept Pharmaceuticals Receives New Coverage from Analysts at FBR Capital Markets (ICPT)
Investment analysts at FBR Capital Markets assumed coverage on shares of Intercept Pharmaceuticals (NASDAQ:ICPT) in a note issued to investors on Friday, TheFlyOnTheWall.com reports. The firm set an “underperform” rating and a $172.00 price target on the stock. FBR Capital Markets’ target price points to a potential downside of 44.09% from the stock’s previous close.
A number of other firms have also recently commented on ICPT. Analysts at TheStreet upgraded shares of Intercept Pharmaceuticals to a “hold” rating in a research note on Thursday. Separately, analysts at Nomura upgraded shares of Intercept Pharmaceuticals to a “positive” rating in a research note on Tuesday. They now have a $456.00 price target on the stock, up previously from $323.00. Finally, analysts at RBC Capital raised their price target on shares of Intercept Pharmaceuticals from $425.00 to $500.00 in a research note on Tuesday. They now have an “outperform” rating on the stock. One research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the stock. Intercept Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $472.91.
In other Intercept Pharmaceuticals news, CEO Mark Pruzanski unloaded 10,000 shares of the stock on the open market in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $226.72, for a total transaction of $2,267,200.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) opened at 296.36 on Friday. Intercept Pharmaceuticals has a 52-week low of $42.41 and a 52-week high of $497.00. The stock has a 50-day moving average of $234.8 and a 200-day moving average of $291.9. The company’s market cap is $6.249 billion.
Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.79) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.12) by $0.67. The company had revenue of $405.40 million for the quarter, compared to the consensus estimate of $400.00 million. Analysts expect that Intercept Pharmaceuticals will post $-13.81 EPS for the current fiscal year.
Intercept Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.